Meeting
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
Authors
Venkatraman Radhakrishnan
Cancer Institute (WIA), Chennai, India
Venkatraman Radhakrishnan , Kritthivasan Venkatakrishnan , Jayachandran Perumal Kalaiyarasi , Gangothri Selvarajan , Nizamudin Mahaboobasha , Paulson Vijaykumar Victor , Malarvizhi Anbazhagan , Deyva Manohari Sivanandam , Swaminathan Rajaraman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
CTRI/2022/03/040906
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12127)
DOI
10.1200/JCO.2023.41.16_suppl.12127
Abstract #
12127
Poster Bd #
495
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.
First Author: Zhigang Liu
Poster
2021 ASCO Annual Meeting
A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE.
First Author: Yoshimasa Shiraishi
Poster
2021 ASCO Annual Meeting
A randomized, double-blind, multicenter, phase III study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving doxorubicin-cyclophosphamide/epirubicin-cyclophosphamide(AC/EC) based highly emetogenic chemotherapy: CONSOLE-BC.
First Author: Junji Tsurutani